NCT03577756

Neurodevelopmental Assessment of Infants With Cystic Fibrosis

Neurodevelopmental Assessment Outcomes of Infants With Cystic Fibrosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 24 (actual)
• Sponsor: Hacettepe University · Academic / Other
• Sex: All
• Age: 24 Months – 36 Months
• Healthy volunteers: Accepted

Summary

Infants included in the study will be divided into two groups as healthy infants and cystic fibrosis infants . Demographic, natal and postnatal information of the infants will be available from patient files. 12 months infants with cystic fibrosis and healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. The assessment outcomes of healthy and cystic fibrosis infants will be compared.

Conditions

• Neurodevelopmental Disorders
• Cystic Fibrosis

Interventions

Type	Name	Description
OTHER	Neurodevelopmental assessments	Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.

Timeline

• Start date: 2018-06-11
• Primary completion: 2021-03-01
• Completion: 2021-03-01
• First posted: 2018-07-05
• Last updated: 2021-04-12

Locations

1 site across 1 country: Turkey (Türkiye)